GSK to invest £275M at three UK manufacturing sites

WCN Editorial Team 28 Jul 2016 EUROPE BUILDINGS

Pharmaceutical and healthcare firm GSK has announced £275M of new investments at three of its manufacturing sites in the UK.

The company is set to invest £92M at its Barnard Castle site, in County Durham, for the construction of an aseptic sterile  manufacturing facility. The site employs 1,100 people and supplies nearly half a million packs of products daily to 140 markets across the world.

At the Montrose site in Scotland, the firm will invest £110M to build a new facility to produce respiratory active ingredients. Currently the site employs more than 450 people.

GSK will also invest £74M to expand its new Ellipta respiratory inhaler manufacturing facility in Ware, Hertfordshire. The site employs 1,200 staff and manufactures innovative respiratory products.

GSK’s CEO Andrew Witty said: “Today’s announcement reflects further investment to support our pharmaceutical pipeline and meet growing demand for our innovative portfolio of newly launched products.

“It is testament to our skilled UK workforce and the country’s leading position in life sciences that we are making these investments in advanced manufacturing here. From their manufacture in the UK, many of these medicines will be sent to patients around the world.”

With 11 websites and newsletters covering all the key areas within the construction industry, World Construction Industry Network is the leading global construction information resource. READ ABOUT US



World Construction Network | is a product of GlobalData. Copyright © 2022 GlobalData. All rights reserved.